<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01060566</url>
  </required_header>
  <id_info>
    <org_study_id>VX09-770-010</org_study_id>
    <nct_id>NCT01060566</nct_id>
  </id_info>
  <brief_title>Study of VX-770 on Midazolam and Rosiglitazone and the Effect of Fluconazole on VX-770</brief_title>
  <official_title>An Open-Label Phase 1 Study to Examine the Effect of VX-770 on Midazolam and Rosiglitazone and the Effect of Fluconazole on VX-770 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vertex Pharmaceuticals Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to evaluate the effects of VX-770 on Midazolam and
      Rosiglitazone, and the effect of Fluconazole on VX-770.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Midazolam, Rosiglitazone and VX 770 pharmacokinetic (PK) parameter</measure>
    <time_frame>11 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fluconazole and VX 770 PK parameters</measure>
    <time_frame>10 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>1Â´ hydroxy midazolam PK parameters in plasma</measure>
    <time_frame>11 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as measured by adverse events, physical examinations, vital signs, ECGs, and clinically significant laboratory assessments</measure>
    <time_frame>21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolites PK parameters in plasma</measure>
    <time_frame>21 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>VX-770</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Midazolam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosiglitazone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VX-770</intervention_name>
    <description>In period 1, subjects will receive a single oral dose of midazolam (2 mg) and on Day 1 and Day 8. Subjects will receive single oral dose of rosiglitazone 4 mg and on Day2 and Day 9. Subjects will receive multiple doses of VX-770 150 mg q12h Day 3-10.</description>
    <arm_group_label>VX-770</arm_group_label>
    <arm_group_label>Midazolam</arm_group_label>
    <arm_group_label>Rosiglitazone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VX-770</intervention_name>
    <description>In period 2, subjects will receive 150 mg VX-770 q12h orally from Day 1 through the morning of Day 8. On the morning of Period 2 Day 1, subjects will receive a 400 mg loading dose of fluconazole. Thereafter, subjects will receive 200 mg fluconazole qd orally from Day 2 through Day 9.</description>
    <arm_group_label>VX-770</arm_group_label>
    <arm_group_label>Fluconazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must be male or female and between 18 and 55 years of age.

          -  Subjects must be judged to be in good health.

          -  Subjects must have a body mass index (BMI) from 18 to 30 kg/m2.

        Exclusion Criteria:

          -  History of any illness that, in the opinion of the investigator or the subject's
             general practitioner, might confound the results of the study or pose an additional
             risk in administering study drug(s) to the subject.

          -  Subjects who have human immunodeficiency virus (HIV), hepatitis C, or active hepatitis
             B.

          -  Female subjects and female partner(s) of male subjects who are pregnant, nursing, or
             planning to become pregnant during the study or within 90 days of the last dose of
             study drug.

          -  History of cardiovascular disease, hypoglycemia, or edema.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>H. Frank Farmer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance CRU, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covan CRU, Inc.</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2010</study_first_submitted>
  <study_first_submitted_qc>February 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2010</study_first_posted>
  <last_update_submitted>April 15, 2010</last_update_submitted>
  <last_update_submitted_qc>April 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 16, 2010</last_update_posted>
  <responsible_party>
    <name_title>Medical Monitor</name_title>
    <organization>Vertex Pharmaceuticals Incorporated</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Rosiglitazone</mesh_term>
    <mesh_term>Fluconazole</mesh_term>
    <mesh_term>Ivacaftor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

